Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$18.66 - $38.58 $11.8 Million - $24.3 Million
-629,770 Reduced 86.01%
102,399 $3.93 Million
Q1 2023

May 15, 2023

SELL
$21.53 - $26.8 $11.5 Million - $14.4 Million
-535,491 Reduced 42.24%
732,169 $16.9 Million
Q4 2022

Feb 14, 2023

SELL
$18.63 - $27.35 $21.9 Million - $32.1 Million
-1,173,094 Reduced 48.06%
1,267,660 $33.2 Million
Q3 2022

Nov 14, 2022

BUY
$17.51 - $23.37 $379,179 - $506,077
21,655 Added 0.9%
2,440,754 $48 Million
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $14.7 Million - $21.9 Million
1,164,899 Added 92.88%
2,419,099 $42.3 Million
Q1 2022

May 16, 2022

SELL
$12.02 - $16.69 $13.2 Million - $18.3 Million
-1,097,543 Reduced 46.67%
1,254,200 $20.5 Million
Q4 2021

Feb 14, 2022

BUY
$10.69 - $16.83 $14.5 Million - $22.8 Million
1,356,873 Added 136.39%
2,351,743 $38.4 Million
Q3 2021

Nov 15, 2021

SELL
$11.5 - $14.86 $5.73 Million - $7.4 Million
-498,030 Reduced 33.36%
994,870 $12.7 Million
Q2 2021

Aug 16, 2021

BUY
$13.6 - $18.98 $4.39 Million - $6.12 Million
322,702 Added 27.58%
1,492,900 $21.1 Million
Q1 2021

May 17, 2021

BUY
$14.17 - $19.11 $3.87 Million - $5.22 Million
272,952 Added 30.42%
1,170,198 $18.2 Million
Q4 2020

Feb 16, 2021

BUY
$11.9 - $20.91 $10.7 Million - $18.8 Million
897,246 New
897,246 $14.2 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.